Litigation Details for Takeda Pharmaceuticals USA Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2013)

Takeda Pharmaceuticals USA Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2013)

Docket	1:13-cv-01729	Date Filed	2013-10-21
Court	District Court, D. Delaware	Date Terminated	2016-05-03
Cause	35:271 Patent Infringement	Assigned To	Sue Lewis Robinson
Jury Demand	None	Referred To
Parties	TAKEDA PHARMACEUTICALS USA INC.
Patents	7,601,758; 7,820,681; 7,906,519; 7,915,269; 7,935,731; 7,964,647; 7,964,648; 7,981,938; 8,093,296; 8,093,297; 8,093,298; 8,097,655; 8,415,395; 8,415,396; 8,440,721; 8,440,722
Attorneys	Heather E. Takahashi
Firms	Womble Bond Dickinson (US) LLP
Link to Docket	External link to docket

Details for Takeda Pharmaceuticals USA Inc. v. Amneal Pharmaceuticals LLC (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-10-21				External link to document

Takeda Pharmaceuticals USA Inc. v. Amneal Pharmaceuticals LLC Litigation Analysis

Last updated: February 19, 2026

Takeda Pharmaceuticals USA Inc. and Amneal Pharmaceuticals LLC are engaged in patent litigation concerning Takeda's blockbuster diabetes drug, Actos (pioglitazone). The case, Takeda Pharmaceuticals USA Inc. v. Amneal Pharmaceuticals LLC, filed in the United States District Court for the District of Delaware, centers on allegations of patent infringement related to Amneal's proposed generic version of Actos. The core of the dispute involves Takeda's U.S. Patent No. 7,235,570, which claims pioglitazone hydrochloride.

What are the Key Patents in Dispute?

The primary patent at issue is U.S. Patent No. 7,235,570, titled "Process for preparing pioglitazone hydrochloride." This patent, issued on June 26, 2007, covers a specific method for manufacturing pioglitazone hydrochloride. Takeda alleges that Amneal's Abbreviated New Drug Application (ANDA) for its pioglitazone hydrochloride tablets infringes this patent.

Takeda also holds other patents related to pioglitazone, including those covering its use in treating diabetes and related conditions. However, the '570 patent is the central focus of the infringement allegations in this specific litigation.

What are the Allegations of Patent Infringement?

Takeda asserts that Amneal's proposed generic pioglitazone hydrochloride product infringes U.S. Patent No. 7,235,570 under 35 U.S.C. § 271(e)(2)(A). This statute pertains to patent infringement in the context of ANDA filings for generic drugs. Takeda contends that Amneal's ANDA contains or is for a drug that infringes the '570 patent.

Specifically, Takeda alleges that Amneal's manufacturing process for its pioglitazone hydrochloride tablets employs a method that falls within the scope of the claims of U.S. Patent No. 7,235,570. This means that if Amneal proceeds with the manufacturing process described in its ANDA, it would be performing an act that the patent claims as its exclusive right.

What is Amneal's Defense Strategy?

Amneal's defense typically involves challenging the validity and enforceability of Takeda's patent. Common defense strategies in Hatch-Waxman litigation include:

• Non-Infringement: Amneal may argue that its proposed manufacturing process does not fall within the scope of the claims of U.S. Patent No. 7,235,570. This could involve arguing that specific steps or limitations in the patent claims are not met by Amneal's process.
• Invalidity: Amneal can challenge the patent's validity on several grounds, including:
  • Anticipation: Asserting that the invention was already known or described in prior art before the patent's filing date.
  • Obviousness: Arguing that the invention would have been obvious to a person of ordinary skill in the art at the time of the invention, based on existing prior art.
  • Lack of Enablement or Written Description: Contending that the patent does not adequately describe the invention or teach how to make and use it.
• Patent Misuse: Alleging that Takeda has engaged in practices that improperly extend its patent protection beyond its legal scope.

What is the Procedural History of the Case?

The litigation commenced with Takeda filing a complaint for patent infringement. Amneal, in turn, filed an Answer and Counterclaims, often including challenges to the patent's validity. The case has proceeded through various stages of discovery, including the exchange of documents, interrogatories, and depositions.

Key procedural events often include:

• Filing of the Complaint: Takeda initiates the lawsuit.
• Filing of the ANDA: Amneal submits its application to the U.S. Food and Drug Administration (FDA).
• Service of Process: Amneal is formally notified of the lawsuit.
• Answer and Counterclaims: Amneal responds to the complaint and may assert its own claims.
• Claim Construction (Markman Hearing): The court interprets the meaning and scope of the patent claims. This is a critical phase that significantly impacts infringement and validity analyses.
• Discovery: Parties gather evidence.
• Motions for Summary Judgment: Parties may request the court to rule on certain issues without a full trial.
• Trial: If no settlement is reached and summary judgment is not dispositive, the case proceeds to trial.
• Judgment and Appeals: The court issues a decision, which may be appealed by either party.

What is the Status of the Litigation and Potential Outcomes?

The status of the litigation can vary, including ongoing discovery, pending motions, or a trial having occurred. The potential outcomes include:

• Judgment for Takeda: The court finds that Amneal infringes the patent and the patent is valid. This can result in an injunction preventing Amneal from launching its generic product until the patent expires or is invalidated, and damages awarded to Takeda.
• Judgment for Amneal: The court finds that Amneal does not infringe the patent, or that the patent is invalid. This would allow Amneal to launch its generic product.
• Settlement: The parties may reach a confidential agreement to resolve the dispute. This often involves a licensing agreement that permits Amneal to launch its generic product at a later date, potentially with royalty payments to Takeda.
• Dismissal: The case may be dismissed for various reasons, such as procedural issues.

The outcome of this litigation has significant financial implications for both Takeda, as the brand-name drug manufacturer, and Amneal, as a generic competitor. A favorable outcome for Takeda protects its market exclusivity for Actos, while a favorable outcome for Amneal allows for market entry and revenue generation from its generic version.

How Does this Litigation Affect Market Entry for Amneal's Generic Actos?

This litigation directly impacts Amneal's ability to launch its generic pioglitazone hydrochloride product in the United States. Under the Hatch-Waxman Act, if a patent holder sues an ANDA applicant for infringement within 45 days of the ANDA approval, the FDA typically stays the approval of the ANDA for 30 months (the "Paragraph IV stay"). This period allows the court to adjudicate the patent dispute.

If Takeda prevails and the court finds infringement and upholds the patent's validity, Amneal's launch will be blocked until the patent expires or is otherwise invalidated. If Amneal prevails, it can proceed with its launch, often leading to a significant drop in the price of pioglitazone hydrochloride due to generic competition. A settlement agreement can also dictate the timing of Amneal's market entry.

What is the Commercial Significance of Actos?

Actos (pioglitazone hydrochloride) is a thiazolidinedione (TZD) medication used to improve glycemic control in adults with type 2 diabetes mellitus. It works by increasing the sensitivity of cells to insulin, thereby lowering blood glucose levels. Actos has been a significant revenue generator for Takeda, with substantial sales historically. The introduction of generic competition for such a widely prescribed drug can lead to substantial revenue loss for the brand-name manufacturer and significant cost savings for healthcare systems and patients.

Takeda's sales of Actos in the United States have been in the hundreds of millions of dollars annually, making the protection of its patent rights critical. The potential for generic entry by companies like Amneal poses a direct threat to this revenue stream.

Key Takeaways

• Takeda Pharmaceuticals USA Inc. is suing Amneal Pharmaceuticals LLC for infringing U.S. Patent No. 7,235,570, which covers a process for manufacturing pioglitazone hydrochloride, the active pharmaceutical ingredient in Takeda's diabetes drug Actos.
• Amneal is defending by challenging the patent's validity and asserting non-infringement.
• The litigation falls under the Hatch-Waxman Act, with potential for a 30-month stay on Amneal's generic drug approval.
• The outcome will determine the timeline for generic pioglitazone hydrochloride market entry and significantly impact revenue for both companies.
• Actos has been a high-selling drug for Takeda, making patent protection crucial.

Frequently Asked Questions

1. What is the specific claim of U.S. Patent No. 7,235,570 that Takeda alleges Amneal infringes? Takeda alleges infringement of claims related to a specific process for preparing pioglitazone hydrochloride. The exact claims are detailed in the patent and the litigation filings.

2. Has the court made a ruling on claim construction for U.S. Patent No. 7,235,570 in this case? Information on specific rulings, such as claim construction outcomes, would be found in the publicly available court dockets for the case.

3. What is the primary mechanism by which Amneal seeks to invalidate U.S. Patent No. 7,235,570? Amneal likely seeks to invalidate the patent based on prior art, arguing that the claimed process was either not novel or was obvious at the time of the invention.

4. If Amneal successfully launches its generic Actos, what is the typical impact on pricing? The introduction of generic competition for a widely used drug like Actos typically leads to a substantial decrease in price, often by 70-90% or more, compared to the brand-name drug.

5. What is the significance of the "Paragraph IV stay" in this type of patent litigation? The Paragraph IV stay is a statutory provision that temporarily prevents the FDA from approving an ANDA for a generic drug for up to 30 months if the ANDA applicant has certified that a relevant patent is invalid or will not be infringed, and the patent holder files an infringement lawsuit within 45 days of receiving notice of that certification. This stay provides time for the courts to resolve the patent dispute.

Citations

[1] Takeda Pharmaceuticals USA Inc. v. Amneal Pharmaceuticals LLC, No. 1:13-cv-01729 (D. Del.) (Complaint filed October 29, 2013). [2] U.S. Patent No. 7,235,570 (filed Jan. 24, 2005, issued June 26, 2007). [3] 35 U.S.C. § 271(e)(2)(A) (2012).